Protein Phosphatase 2A, Autophagy, and Drug Resistance in Candida albicans Biofilms

Study Background and Research Question

Candida albicans is a leading opportunistic fungal pathogen, notorious for its ability to form robust biofilms on mucosal surfaces and medical devices. These biofilms confer marked resistance to antifungal treatments, presenting major challenges in both clinical and research settings (reference). While azole antifungals such as Fluconazole, a fungal cytochrome P450 enzyme 14α-demethylase inhibitor, remain a mainstay in therapy and research (internal), emerging resistance—particularly within biofilms—necessitates deeper mechanistic understanding. The regulation of autophagy, a cellular self-degradation process, has recently been implicated in fungal stress responses and drug resistance, but the precise signaling mechanisms remain unclear.

Key Innovation from the Reference Study

The central innovation of Jiadi Shen et al.'s 2025 study is the identification of protein phosphatase 2A (PP2A) as a pivotal regulator of autophagy-mediated drug resistance in C. albicans biofilms (reference). The authors demonstrated that PP2A, via its catalytic subunit encoded by PPH21, promotes phosphorylation of ATG proteins, specifically Atg13 and Atg1, thereby enhancing autophagic flux. This induction of autophagy contributes to both biofilm maturation and increased resistance to antifungal agents. Notably, loss of PPH21 abrogates these processes, sensitizing biofilms to treatment.

Methods and Experimental Design Insights

The researchers employed a combination of genetic, pharmacological, and in vivo approaches:

• PPH21 Knockout: Construction of a pph21Δ/Δ mutant to assess the role of PP2A in biofilm formation and drug response.
• Autophagy Modulation: Treatment with rapamycin (autophagy activator) to investigate the functional link between autophagy and drug resistance.
• Expression Analysis: Quantification of ATG proteins (Atg13, Atg1) by immunoblotting to evaluate autophagy signaling.
• Drug Susceptibility Assays: Exposure of biofilms to antifungal agents, including azoles, with comparative analysis of wild-type and mutant strains.
• Oxidative Stress Measurement: Assessment of the biofilm’s oxidative stress tolerance under varying autophagy conditions.
• In Vivo Efficacy: A mouse model of oral C. albicans infection to determine the therapeutic impact of antifungal agents in the context of altered autophagy.

Protocol Parameters

• assay | 10 μg/mL Fluconazole | in vitro Candida albicans growth inhibition | standard concentration for susceptibility testing | product_spec
• assay | 80 mg/kg/day Fluconazole (i.p.) | in vivo mouse infection model | dose shown to significantly reduce fungal burden | product_spec
• assay | Rapamycin (concentration not specified) | autophagy induction in C. albicans biofilm | used to mechanistically probe PP2A-autophagy axis | reference
• assay | Atg13/Atg1 immunoblotting | autophagy signaling evaluation | quantifies changes in autophagy pathway activity | reference
• assay | PPH21 knockout construction | genetic dissection of PP2A function | reveals PP2A’s role in autophagy and drug resistance | reference
• assay | Oxidative stress tolerance assay | biofilm stress response measurement | links autophagy to environmental stress adaptation | reference
• assay | Antifungal efficacy in mouse oral infection model | in vivo drug performance assessment | models clinical relevance of biofilm resistance | reference

Core Findings and Why They Matter

Key results from this work can be summarized as follows:

• PPH21 Expression Drives Biofilm Formation and Drug Resistance: Deletion of PPH21 resulted in diminished biofilm mass and increased susceptibility to antifungal agents, highlighting PP2A as a central player in biofilm resilience (reference).
• Autophagy Activation Enhances Resistance: Pharmacological induction of autophagy with rapamycin increased biofilm robustness and antifungal resistance, effects that were abolished in the pph21Δ/Δ mutant.
• ATG Protein Phosphorylation is PP2A-Dependent: Reduced levels of phosphorylated Atg13 and Atg1 in PP2A-deficient strains confirmed that autophagy signaling is directly regulated by PP2A activity.
• Clinical Relevance in Animal Models: Activation of autophagy diminished antifungal efficacy in a mouse model of oral C. albicans infection, whereas PP2A-deficient strains were more effectively controlled by treatment.

By elucidating this PP2A–ATG–autophagy axis, the study positions autophagy modulation as a promising strategy to overcome biofilm-driven antifungal resistance.

Comparison with Existing Internal Articles

Several recent reviews and guides highlight the importance of Fluconazole as an ergosterol biosynthesis inhibitor and standard for antifungal susceptibility testing in C. albicans research (internal, internal). These resources provide detailed workflows and troubleshooting for maximizing reproducibility in both in vitro and in vivo models. Notably, the internal article "Decoding Candida albicans Drug Resistance" (internal) prefigures the importance of autophagy and PP2A in resistance mechanisms, but the present reference study delivers the first direct experimental evidence linking PP2A-dependent ATG protein phosphorylation to biofilm-mediated drug resistance. While prior protocols focus on optimizing Fluconazole dosing and assay conditions, this paper extends the mechanistic understanding by connecting these workflows to cellular signaling pathways modulating resistance.

Limitations and Transferability

While the study provides robust genetic and pharmacological evidence in laboratory strains and a mouse oral infection model, several limitations are noted:

• The concentration and in vivo relevance of autophagy modulators (e.g., rapamycin) require further optimization and validation in clinical settings.
• Experiments were focused on a single fungal species and biofilm context; applicability to other pathogenic fungi or systemic infections remains to be established.
• Direct clinical translation will necessitate consideration of host-pathogen interactions, immune responses, and pharmacokinetics of both antifungal and autophagy-targeting agents.

Nonetheless, the mechanistic clarity provided by genetic knockout and in vivo rescue experiments supports the generalizability of PP2A–autophagy signaling as a targetable axis for future antifungal strategies.

Research Support Resources

Researchers seeking to model or modulate antifungal drug resistance in C. albicans can employ standardized reagents and protocols featured in this and related studies. For example, Fluconazole (SKU B2094) from APExBIO is widely adopted as a reference fungal cytochrome P450 enzyme 14α-demethylase inhibitor, with consistent performance in both in vitro and in vivo Candida albicans infection models (source: product_spec). Its use facilitates reproducible antifungal susceptibility testing and mechanistic studies of drug resistance, supporting workflows aligned with the latest mechanistic insights.